All Bristol-Myers Squibb articles
-
BusinessProtein degrader approval offers hope to relapsed multiple myeloma patients
Highly potent molecular glue drug iberdomide doubles the number of patients reaching fewer than one myeloma cell per 100,000 in bone marrow
-
OpinionMessy megamergers
Rumoured merger between AstraZeneca and Bristol Myers Squibb has collapsed, and that’s probably a good thing
-
BusinessDrug companies reluctantly accept state price negotiations
As legal challenges fall flat, will industry’s claims of stifled innovation be borne out?
-
-
BusinessPfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment
-
BusinessBMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
ResearchBaran and Blackmond team up to wave farewell to tough ether syntheses
Oxidative decarboxylation produces carbocations that greatly speed up hindered ether production
-
ResearchLigand selector steers C–N cross-couplings down most sustainable path
Tool is step towards strategy that considers reagents and reactants above and below the arrow
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
-
BusinessBMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessLong road to recovery for Puerto Rico pharmaceuticals
As inhabitants begin to rebuild their lives after the devastation of hurricane Maria, the island’s drug manufacturers are recovering slowly
-
BusinessBristol-Myers Squibb bags immunotherapy unicorn
Deal will add to pharma giant’s cancer portfolio
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessBristol-Myers Squibb planning huge reorganisation in the US
Job losses likely as Hopewell, New Jersey site will close by 2020
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research